BRIDGEWATER, N.J., April 11, 2013 /PRNewswire/ -- Allegra Anti-Itch Cooling Relief Cream and Allegra Anti-Itch Intensive Relief Cream are now available in drug, grocery and mass merchandiser stores nationwide. Chattem, Inc., the Consumer Healthcare Division of Sanofi US and the makers of Allegra Allergy, introduced the Anti-Itch Creams to its family of products to help provide itch relief from reactions to skin irritations.
Allegra Anti-Itch Cooling Relief provides fast cooling relief for hot, itchy skin while Allegra Anti-Itch Intensive Relief provides moisturizing relief for itchy, dry and irritated skin. Both products provide temporary relief from the pain and itching associated with insect bites, minor skin irritations, sunburn, rashes due to poison ivy, poison oak or poison sumac, and minor cuts and scrapes. They also temporarily protect and help relieve chapped or cracked skin.
“We identified an opportunity in the topical anti-itch category and leveraged our experience with Allegra Allergy to introduce a new product for common skin irritations that not only helps stop the itch but also provides a moisturizing benefit,” said John Stroud, Executive Vice President, Marketing, Chattem.
Itchy skin can be triggered by a chemical in a person’s body called histamine. Histamine is a person’s immune system reacting to an irritant, like an insect bite or poison ivy. Allegra Anti-Itch Cream acts as an antihistamine, going beneath the surface of the skin to stop the itch at its source. In addition, the moisturizers and vitamins A, C and E in Allegra Anti-Itch Cream help soothe the skin, and the allantoin protects the skin while it gets back to normal after scratching.
Allegra Anti-Itch Cream is indicated for adults and children ages 2 and up. The suggested retail price is $4.99-$6.99. For additional information on the Allegra family of products, please visit www.allegra.com. Follow us on Facebook and Twitter.
About Allegra®
Allegra Allergy has been providing allergy sufferers with relief of symptoms from indoor and outdoor allergies for more than 15 years. The Allegra family of products is available without a prescription in drug, grocery, mass merchandiser and club stores nationwide.
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi is the holding company of a consolidated group of subsidiaries and operates in the United States as Sanofi US, also referred to as sanofi-aventis U.S. LLC. For more information on Sanofi US, please visit http://www.sanofi.us or call 1-800-981-2491.
AboutChattem
In March 2010, Chattem, Inc. became a wholly-owned subsidiary of the sanofi-aventis Group, as the consumer healthcare division of Sanofi US. Chattem is more than 130 years old and is a leading manufacturer and marketer of branded consumer healthcare products, toiletries and dietary supplements across niche market segments in the United States. For more information, please visit Chattem’s website at www.chattem.com
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2011. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
SOURCE Sanofi
